Intra-abdominal Sepsis: Newer Interventional and Antimicrobial Therapies

Infectious Disease Clinics of North America

Volumn 23, Issue 3, 2009, Pages 593-608

  Solomkin, Joseph S ^a   Mazuski, John ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abscess; Antibiotic; Microbiology; Percutaneous drainage; Peritonitis; Severity; Source control

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANIDULAFUNGIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CASPOFUNGIN; CEFEPIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; FLUCONAZOLE; LINEZOLID; MEROPENEM; METRONIDAZOLE; MICAFUNGIN; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABDOMINAL SURGERY; ABSCESS DRAINAGE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FLUID RESUSCITATION; FLUID THERAPY; HEMORRHAGIC SHOCK; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; LAPAROTOMY; NONHUMAN; PERCUTANEOUS DRAINAGE; PERITONITIS; REVIEW; SEPSIS; SEPTIC SHOCK; TREATMENT DURATION; TREATMENT OUTCOME;

ABDOMINAL ABSCESS; ANTI-BACTERIAL AGENTS; DRAINAGE; HUMANS; INTENSIVE CARE UNITS; PERITONITIS; SEPSIS;

EID: 68049142564     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.04.007     Document Type: Review

References (116)

1. Moss M. Epidemiology of sepsis: race, sex, and chronic alcohol abuse. Clin Infect Dis 41 Suppl 7 (2005) S490-S497
2. Martin G.S., Mannino D.M., Eaton S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003) 1546-1554
3. Bohnen J.M., Marshall J.C., Fry D.E., et al. Clinical and scientific importance of source control in abdominal infections: summary of a symposium. Can J Surg 42 (1999) 122-126
4. Jimenez M.F., and Marshall J.C. Source control in the management of sepsis. Intensive Care Med 27 Suppl 1 (2001) S49-S62
5. Marshall J.C., Maier R.V., Jimenez M., et al. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 32 (2004) S513-S526
6. Knaus W.A., Wagner D.P., Draper E.A., et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. [see comments]. Chest 100 (1991) 1619-1636
7. Le Gall J.R., Lemeshow S., and Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. [published erratum appears in JAMA 1994 May 4;271(17):1321]. JAMA 270 (1993) 2957-2963
8. Lemeshow S., and Le Gall J.R. Modeling the severity of illness of ICU patients. A systems update. JAMA 272 (1994) 1049-1055
9. Meyer A.A., Messick W.J., Young P., et al. Prospective comparison of clinical judgment and APACHE II score in predicting the outcome in critically ill surgical patients. J Trauma 32 (1992) 747-753
10. Swenson B.R., Metzger R., Hedrick T.L., et al. Choosing antibiotics for intra-abdominal infections: what do we mean by "high risk"?. Surg Infect (Larchmt) 10 (2009) 29-39
11. Klevens R.M., Morrison M.A., Nadle J., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298 (2007) 1763-1771
12. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36 (2008) 296-327
13. Hess J.R., and Holcomb J.B. Transfusion practice in military trauma. Transfus Med 18 (2008) 143-150
14. Beekley A.C. Damage control resuscitation: a sensible approach to the exsanguinating surgical patient. Crit Care Med 36 (2008) S267-S274
15. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 (2001) 1368-1377
16. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34 (2006) 1589-1596
17. van Nieuwenhoven C.A., Buskens E., van Tiel F.H., et al. Relationship between methodological trial quality and the effects of selective digestive decontamination on pneumonia and mortality in critically ill patients. JAMA 286 (2001) 335-340
18. Lodise Jr. T.P., Patel N., Kwa A., et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 51 (2007) 3510-3515
19. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
20. Bratzler D.W., and Houck P.M. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 189 (2005) 395-404
21. Bratzler D.W., and Hunt D.R. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis 43 (2006) 322-330
22. Shlaes D.M., Gerding D.N., John Jr. J.F., et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 25 (1997) 584-599
23. Koperna T., and Schulz F. Prognosis and treatment of peritonitis. Do we need new scoring systems?. Arch Surg 131 (1996) 180-186
24. Koperna T., and Schulz F. Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intraabdominal infection. World J Surg 24 (2000) 32-37
25. Mulier S., Penninckx F., Verwaest C., et al. Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients. World J Surg 27 (2003) 379-384
26. Grunau G., Heemken R., and Hau T. Predictors of outcome in patients with postoperative intra-abdominal infection. Eur J Surg 162 (1996) 619-625
27. Hall J.C., Heel K.A., Papadimitriou J.M., et al. The pathobiology of peritonitis. Gastroenterology 114 (1998) 185-196
28. Li J.C., and Yu S.M. Study on the ultrastructure of the peritoneal stomata in humans. Acta Anat (Basel) 141 (1991) 26-30
29. Michailova K.N. Ultrastructural observations on the human visceral pleura. Eur J Morphol 35 (1997) 125-135
30. Michailova K.N. Postinflammatory changes of the diaphragmatic stomata. Ann Anat 183 (2001) 309-317
31. Shao X.J., Ohtani O., Saitoh M., et al. Development of diaphragmatic lymphatics: the process of their direct connection to the peritoneal cavity. Arch Histol Cytol 61 (1998) 137-149
32. Li J., Zhao Z., Zhou J., et al. A study of the three-dimensional organization of the human diaphragmatic lymphatic lacunae and lymphatic drainage units. Ann Anat 178 (1996) 537-544
33. bu-Hijleh M.F., Habbal O.A., and Moqattash S.T. The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J Anat 186 Pt 3 (1995) 453-467
34. Akinci D., Akhan O., Ozmen M.N., et al. Percutaneous drainage of 300 intraperitoneal abscesses with long-term follow-up. Cardiovasc Intervent Radiol 28 (2005) 744-750
35. Betsch A., Wiskirchen J., Trubenbach J., et al. CT-guided percutaneous drainage of intra-abdominal abscesses: APACHE III score stratification of 1-year results. Acute physiology, age, chronic health evaluation. Eur Radiol 12 (2002) 2883-2889
36. Bufalari A., Giustozzi G., and Moggi L. Postoperative intraabdominal abscesses: percutaneous versus surgical treatment. Acta Chir Belg 96 (1996) 197-200
37. Theisen J., Bartels H., Weiss W., et al. Current concepts of percutaneous abscess drainage in postoperative retention. J Gastrointest Surg 9 (2005) 280-283
38. Pruett T.L., and Simmons R.L. Status of percutaneous catheter drainage of absceses. Surg Clin North Am 68 (1988) 89-105
39. Gerzof S.G., Robbins A.H., and Birkett D.H. Computed tomography in the diagnosis and management of abdominal abscesses. Gastrointest Radiol 3 (1978) 287-294
40. Gerzof S.G., Johnson W.C., Robbins A.H., et al. Expanded criteria for percutaneous abscess drainage. Arch Surg 120 (1985) 227-232
41. Gerzof S.G., Robbins A.H., Johnson W.C., et al. Percutaneous catheter drainage of abdominal abscesses: a five-year experience. N Engl J Med 305 (1981) 653-657
42. vanSonnenberg E., Mueller P.R., and Ferrucci Jr. J.T. Percutaneous drainage of 250 abdominal abscesses and fluid collections. Part I: results, failures, and complications. Radiology 151 (1984) 337-341
43. Levison M.A. Percutaneous versus open operative drainage of intra-abdominal abscesses. Infect Dis Clin North Am 6 (1992) 525-544
44. Sones P.J. Percutaneous drainage of abdominal abscesses. Am J Roentgenol 142 (1984) 35-39
45. Maher M.M., Gervais D.A., Kalra M.K., et al. The inaccessible or undrainable abscess: how to drain it. Radiographics 24 (2004) 717-735
46. van R.O., Mahler C.W., Boer K.R., et al. Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis: a randomized trial. JAMA 298 (2007) 865-872
47. Schein M., Wittmann D.H., Aprahamian C.C., et al. The abdominal compartment syndrome: the physiological and clinical consequences of elevated intra-abdominal pressure. J Am Coll Surg 180 (1995) 745-753
48. Miller P.R., Meredith J.W., Johnson J.C., et al. Prospective evaluation of vacuum-assisted fascial closure after open abdomen: planned ventral hernia rate is substantially reduced. Ann Surg 239 (2004) 608-614
49. Fabian T.C. Damage control in trauma: laparotomy wound management acute to chronic. Surg Clin North Am 87 (2007) 73-93 vi
50. Schein M. Planned relaparotomies and laparostomy. In: Schein M., and Marshall J.C. (Eds). A guide to the management of surgical infections (2003), Springer, Heidelberg 412-423
51. Paterson D.L., Rossi F., Baquero F., et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 55 (2005) 965-973
52. Yellin A.E., Heseltine P.N., Berne T.V., et al. The role of Pseudomonas species in patients treated with ampicillin and Sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 161 (1985) 303-307
53. Bradley J.S., Behrendt C.E., Arrieta A.C., et al. Convalescent phase outpatient parenteral antiinfective therapy for children with complicated appendicitis. Pediatr Infect Dis J 20 (2001) 19-24
54. Lin W.J., Lo W.T., Chu C.C., et al. Bacteriology and antibiotic susceptibility of community-acquired intra-abdominal infection in children. J Microbiol Immunol Infect 39 (2006) 249-254
55. Christou N.V., Barie P.S., Dellinger E.P., et al. Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. Arch Surg 128 (1993) 193-198 [discussion: 198-9]
56. Dellinger E.P., Wertz M.J., Meakins J.L., et al. Surgical infection stratification system for intra-abdominal infection. Multicenter trial. Arch Surg 120 (1985) 21-29
57. Nystrom P.O., Bax R., Dellinger E.P., et al. Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe. [Review]. World J Surg 14 (1990) 148-158
58. Ohmann C. Prognostic scores and design of clinical studies. Infection 26 (1998) 342-344
59. Ohmann C., Wittmann D.H., and Wacha H. Prospective evaluation of prognostic scoring systems in peritonitis. Peritonitis Study Group. Eur J Surg 159 (1993) 267-274
60. Wacha H., Hau T., Dittmer R., et al. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg 384 (1999) 24-32
61. Mosdell D.M., Morris D.M., Voltura A., et al. Antibiotic treatment for surgical peritonitis. Ann Surg 214 (1991) 543-549
62. Bieluch V.M., Cuchural G.J., Snydman D.R., et al. Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates. Diagn Microbiol Infect Dis 7 (1987) 119-126
63. Snydman D.R., Cuchural Jr. G.J., McDermott L., et al. Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis. Antimicrob Agents Chemother 36 (1992) 540-544
64. Oh H., Nord C.E., Barkholt L., et al. Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone. Infection 28 (2000) 272-277
65. Sullivan A., Edlund C., and Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 1 (2001) 101-114
66. Aldridge K.E., and O'Brien M. In vitro susceptibilities of the Bacteroides fragilis group species: change in isolation rates significantly affects overall susceptibility data. J Clin Microbiol 40 (2002) 4349-4352
67. Cuchural Jr. G.J., Tally F.P., Jacobus N.V., et al. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother 32 (1988) 717-722
68. Snydman D.R., McDermott L., Cuchural Jr. G.J., et al. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. Clin Infect Dis 23 Suppl 1 (1996) S54-S65
69. Snydman D.R., Jacobus N.V., McDermott L.A., et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother 43 (1999) 2417-2422
70. Snydman D.R., Jacobus N.V., McDermott L.A., et al. National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000. Clin Infect Dis 35 (2002) S126-S134
71. Golan Y., McDermott L.A., Jacobus N.V., et al. Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 52 (2003) 208-213
72. Goldstein E.J., Citron D.M., Warren Y.A., et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 50 (2006) 148-155
73. Snydman D.R., Jacobus N.V., McDermott L.A., et al. In vitro activities of newer quinolones against Bacteroides group organisms. Antimicrob Agents Chemother 46 (2002) 3276-3279
74. Snydman D.R., Jacobus N.V., McDermott L.A., et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 51 (2007) 1649-1655
75. Montravers P., Gauzit R., Muller C., et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 23 (1996) 486-494
76. Cohn S.M., Lipsett P.A., Buchman T.G., et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 232 (2000) 254-262
77. Ohlin B., Cederberg A., Forssell H., et al. Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections. Eur J Surg 165 (1999) 875-884
78. Polk Jr. H.C., Fink M.P., Laverdiere M., et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group. Am Surg 59 (1993) 598-605
79. Sirinek K.R., and Levine B.A. A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Surg Gynecol Obstet 172 Suppl (1991) 30-35
80. Walker A.P., Nichols R.L., Wilson R.F., et al. Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 217 (1993) 115-121
81. Burnett R.J., Haverstock D.C., Dellinger E.P., et al. Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 118 (1995) 716-721
82. Montravers P., Dupont H., Gauzit R., et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 34 (2006) 646-652
83. Montravers P., Lepape A., Dubreuil L., et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 63 (2009) 785-794
84. Montravers P., Chalfine A., Gauzit R., et al. Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann Surg 239 (2004) 409-416
85. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
86. Pappas P.G., Rex J.H., Sobel J.D., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 (2004) 161-189
87. Calandra T., Bille J., Schneider R., et al. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 2 (1989) 1437-1440
88. Solomkin J.S., Flohr A.B., Quie P.G., et al. The role of Candida in intraperitoneal infections. Surgery 88 (1980) 524-530
89. Eggimann P., Francioli P., Bille J., et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 27 (1999) 1066-1072
90. Mean M., Marchetti O., and Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 12 (2008) 204
91. Hof H. Developments in the epidemiolgy of invasive fungal infections-implications for the empiric and targeted antifungal therapy. Mycoses 51 Suppl 1 (2008) 1-6
92. Pfaller M.A., Boyken L., Hollis R.J., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46 (2008) 150-156
93. Pfaller M.A., Messer S.A., Boyken L., et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods. J Clin Microbiol 45 (2007) 70-75
94. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
95. Reboli A.C., Rotstein C., Pappas P.G., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356 (2007) 2472-2482
96. Pappas P.G., Rotstein C.M., Betts R.F., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45 (2007) 883-893
97. Blot S., and De Waele J.J. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 65 (2005) 1611-1620
98. Sitges-Serra A., Lopez M.J., Girvent M., et al. Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 89 (2002) 361-367
99. Mascini E.M., and Bonten M.J. Vancomycin-resistant enterococci: consequences for therapy and infection control. Clin Microbiol Infect 11 Suppl 4 (2005) 43-56
100. Leavis H.L., Willems R.J., Top J., et al. Epidemic and nonepidemic multidrug-resistant Enterococcus faecium. Emerg Infect Dis 9 (2003) 1108-1115
101. Bonten M.J., Willems R., and Weinstein R.A. Vancomycin-resistant enterococci: why are they here, and where do they come from?. Lancet Infect Dis 1 (2001) 314-325
102. Mazuski J.E. Vancomycin-resistant enterococcus: risk factors, surveillance, infections, and treatment. Surg Infect (Larchmt) 9 (2008) 567-571
103. Fierobe L., Decre D., Muller C., et al. Methicillin-resistant Staphylococcus aureus as a causative agent of postoperative intra-abdominal infection: relation to nasal colonization. Clin Infect Dis 29 (1999) 1231-1238
104. Patel M., Kumar R.A., Stamm A.M., et al. USA300 genotype community-associated methicillin-resistant Staphylococcus aureus as a cause of surgical site infections. J Clin Microbiol 45 (2007) 3431-3433
105. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2 (2004) 289-300
106. Edmiston C.E., Krepel C., Kelly H., et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels?. Surgery 136 (2004) 738-747
107. Pai M.P., and Bearden D.T. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 27 (2007) 1081-1091
108. Lamp K.C., Freeman C.D., Klutman N.E., et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 36 (1999) 353-373
109. Sprandel K.A., Drusano G.L., Hecht D.W., et al. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagn Microbiol Infect Dis 55 (2006) 303-309
110. Lau A.H., Emmons K., and Seligsohn R. Pharmacokinetics of intravenous metronidazole at different dosages in healthy subjects. Int J Clin Pharmacol Ther Toxicol 29 (1991) 386-390
111. Ljungberg B., Nilsson-Ehle I., and Ursing B. Metronidazole: pharmacokinetic observations in severely ill patients. J Antimicrob Chemother 14 (1984) 275-283
112. Solomkin J.S., Mazuski J.E., Baron E.J., et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 37 (2003) 997-1005
113. Mazuski J.E., Sawyer R.G., Nathens A.B., et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surgical Infections 3 (2002) 161-174
114. Mazuski J.E., Sawyer R.G., Nathens A.B., et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surgical Infections 3 (2002) 175-234
115. Hedrick T.L., Evans H.L., Smith R.L., et al. Can we define the ideal duration of antibiotic therapy?. Surg Infect (Larchmt) 7 (2006) 419-432
116. Lennard E.S., Dellinger E.P., Wertz M.J., et al. Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis. Ann Surg 195 (1982) 19-24